CLS report to EU Horizon2020 shows continued promising survival results for imILT treatment of pancreatic cancer
Clinical Laserthermia Systems (CLS) (publ), today submitted the first part of the report to the EU that marks the conclusion of the project that CLS began in 2016, and that received just over SEK 20 million in project funding from the EU Framework Programme for Research and Innovation, Horizon 2020. The report contains confirmation of the positive results, previously announced by CLS, regarding the survival of patients with pancreatic cancer who have received imILT therapy. CLS and the two hospitals that conducted the pancreatic cancer study now plan to continue to work together and will